27Nov 2023
Indian Immunologicals Ltd's HBI Marks 25 Years of Vaccine Excellence, Launches New Measles Rubella Vaccine

Indian Immunologicals Ltd's HBI Marks 25 Years of Vaccine Excellence, Launches New Measles Rubella Vaccine

Indian Immunologicals Ltd (IIL), a subsidiary of the National Dairy Development Board, celebrated the 25th anniversary of its Human Biologicals Institute (HBI). Established in 1998, HBI has become a global leader in vaccine manufacturing, producing the world's largest supply of anti-rabies vaccines and key vaccines for India's immunization program. On this occasion, HBI launched MebellaM, a Measles Rubella (MR) Vaccine, and announced the upcoming release of Havisure, India's first indigenous Hepatitis A Vaccine, by March 2024, reinforcing its commitment to addressing healthcare challenges through innovative vaccines.

  • #family health

Like

Save

Share